Just in six months since launching the GlucoMen Day PUMP, a blood sugar control solution, in Europe, EOFlow is facing a sales suspension on the product. Insulet, the No. 1 insulin pump company in Germany, has been granted a preliminary injunction related to a patent in Germany, halting local sales of the product.
Much attention is being paid to whether the suspension will be extended to other European markets. EOFlow plans to continue its legal defense, saying that it has expected such a patent lawsuit against the product.
According to industry sources on March 24, the Düsseldorf, German Court recently granted a preliminary injunction against Menarini’s German subsidiary, Berlin Chemie, to suspend sales of the GlucoMen Day PUMP. The product was developed by Korean insulin pump developer EOFlow. EOFlow signed a five-year, 150 billion won (US$150 million) contract with Menarini in late 2021 to exclusively supply the wearable insulin pump EOPatch.
However, just in six months since the GlucoMen Day PUMP’s launch, it was taken away from the shelves in the German market as the German court accepted the preliminary injunction against the sale of the insulin pump’s fluid supply device patent filed by rival company Insulet. Earlier, Insulet filed a similar patent dispute against Metrum Group, which entered the German market earlier, over a patent related to the technology. It is reportedly in the process of appealing to the Düsseldorf Higher Regional Court.
Meanwhile, the Saudi International Industrial Village Company (SIIVC) was conducting due diligence on EOFlow, recently said Korean media outlets and industry sources, but the company denied it.